Quizartinib (AC220): Selective FLT3 Inhibitor for Acute M...

2026-01-20

Quizartinib (AC220) is a second-generation, highly selective FLT3 inhibitor optimized for acute myeloid leukemia (AML) research. Its nanomolar potency and mechanism-based selectivity make it a benchmark tool for FLT3 signaling pathway interrogation and resistance studies. This article provides atomic, verifiable claims about Quizartinib's activity, selectivity, and practical workflow integration.